Moderna reaches "landmark moment" in Melanoma vaccine trial

Moderna, a biotech company, has announced promising results from a Phase 3 trial of its mRNA vaccine for treating melanoma, the deadliest form of skin cancer. The trial involved over 1,100 patients whose melanoma had progressed to advanced stages. According to the company, the vaccine showed significant improvement in keeping patients cancer-free for longer periods. This breakthrough is seen as a "landmark moment" for mRNA vaccines against cancer, and Moderna's stock price surged more than double on Wednesday morning following the announcement. The vaccine works by delivering synthetic mRNA into cells that targets specific mutations present in the patient's tumor, using artificial intelligence to identify which mutations to target. If approved, this vaccine could potentially prevent melanoma from returning or spreading in patients who have undergone treatment.